tetano
Editor, Senior Moderator
Heliyon
. 2023 Sep 5;9(9):e19609.
doi: 10.1016/j.heliyon.2023.e19609. eCollection 2023 Sep. Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis
Dan Dou[SUP] 1 [/SUP], Fangyi Zhang[SUP] 2 [/SUP], Xin Deng[SUP] 1 [/SUP], Yun Ma[SUP] 3 [/SUP], Shuqing Wang[SUP] 3 [/SUP], Xingyu Ji[SUP] 1 [/SUP], Xihan Zhu[SUP] 1 [/SUP], Dianpeng Wang[SUP] 2 [/SUP], Shengsheng Zhang[SUP] 1 [/SUP], Luqing Zhao[SUP] 1 [/SUP]
Affiliations
Background and objectives: There are concerns about the serological responses to Coronavirus disease 2019 (COVID-19) vaccines in inflammatory bowel disease (IBD) patients, particularly those receiving anti-TNF therapy. This study aimed to systematically evaluate the efficacy of COVID-19 vaccines in IBD patients receiving anti-TNF therapy.
Methods: Electronic databases were searched to identify relevant studies. We calculated pooled seroconversion rate after COVID-19 vaccination and subgroup analysis for vaccine types and different treatments were performed. Additionally, we estimated pooled rate of T cell response, neutralization response, and breakthrough infections in this population.
Results: 32 studies were included in the meta-analysis. IBD patients receiving anti-TNF therapy had relatively high overall seroconversion rate after complete vaccination, with no statistical difference in antibody responses associated with different drug treatments. The pooled positivity rate of T cell response was 0.85 in IBD patients receiving anti-TNF therapy. Compared with healthy controls, the positivity of neutralization assays was significantly lower in IBD patients receiving anti-TNF therapy. The pooled rate of breakthrough infections in IBD patients receiving anti-TNF therapy was 0.04.
Conclusions: COVID-19 vaccines have shown good efficacy in IBD patients receiving anti-TNF therapy. However, IBD patients receiving anti-TNF have a relatively high rate of breakthrough infections and a low level of neutralization response.
Keywords: Anti-TNF therapy; COVID-19 vaccines; Inflammatory bowel disease; Meta-analysis; Serological response.
. 2023 Sep 5;9(9):e19609.
doi: 10.1016/j.heliyon.2023.e19609. eCollection 2023 Sep. Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis
Dan Dou[SUP] 1 [/SUP], Fangyi Zhang[SUP] 2 [/SUP], Xin Deng[SUP] 1 [/SUP], Yun Ma[SUP] 3 [/SUP], Shuqing Wang[SUP] 3 [/SUP], Xingyu Ji[SUP] 1 [/SUP], Xihan Zhu[SUP] 1 [/SUP], Dianpeng Wang[SUP] 2 [/SUP], Shengsheng Zhang[SUP] 1 [/SUP], Luqing Zhao[SUP] 1 [/SUP]
Affiliations
- PMID: 37810049
- PMCID: PMC10558877
- DOI: 10.1016/j.heliyon.2023.e19609
Background and objectives: There are concerns about the serological responses to Coronavirus disease 2019 (COVID-19) vaccines in inflammatory bowel disease (IBD) patients, particularly those receiving anti-TNF therapy. This study aimed to systematically evaluate the efficacy of COVID-19 vaccines in IBD patients receiving anti-TNF therapy.
Methods: Electronic databases were searched to identify relevant studies. We calculated pooled seroconversion rate after COVID-19 vaccination and subgroup analysis for vaccine types and different treatments were performed. Additionally, we estimated pooled rate of T cell response, neutralization response, and breakthrough infections in this population.
Results: 32 studies were included in the meta-analysis. IBD patients receiving anti-TNF therapy had relatively high overall seroconversion rate after complete vaccination, with no statistical difference in antibody responses associated with different drug treatments. The pooled positivity rate of T cell response was 0.85 in IBD patients receiving anti-TNF therapy. Compared with healthy controls, the positivity of neutralization assays was significantly lower in IBD patients receiving anti-TNF therapy. The pooled rate of breakthrough infections in IBD patients receiving anti-TNF therapy was 0.04.
Conclusions: COVID-19 vaccines have shown good efficacy in IBD patients receiving anti-TNF therapy. However, IBD patients receiving anti-TNF have a relatively high rate of breakthrough infections and a low level of neutralization response.
Keywords: Anti-TNF therapy; COVID-19 vaccines; Inflammatory bowel disease; Meta-analysis; Serological response.